Vaccinex, a biotechnology company, is currently facing the possibility of being delisted from the Nasdaq due to financial struggles. This news has caused their shares to drop by a significant 62%. The company is working to address these challenges in order to maintain its listing on the stock exchange. Investors are closely watching the situation as Vaccinex navigates through this difficult period.